Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 5/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | IGF2R | P11717 | 6/20 | 0.37 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.37 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13760997 | 0.89 | GJB2 (0.47) | GJB2TNFIGF2RGBA1MAPK1 | |
| SCHEMBL18653473 | 0.89 | GJB2 (0.50) | GJB2TNFIGF2RGBA1MAPK1 | |
| SCHEMBL18653423 | 0.89 | GJB2 (0.50) | GJB2TNFIGF2RGBA1MAPK1 | |
| SCHEMBL6408945 | 0.86 | SSTR4 (0.48) | GJB2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL8686677 | 0.85 | GBA1 (0.53) | GJB2TNFIGF2RGBA1MAPK1 | |
| SCHEMBL8691523 | 0.85 | GBA1 (0.53) | GJB2TNFIGF2RGBA1MAPK1 | |
| SCHEMBL12447492 | 0.85 | GJB2 (0.53) | GJB2TNFIGF2RGBA1MAPK1 | |
| SCHEMBL8686418 | 0.85 | GBA1 (0.53) | GJB2TNFIGF2RGBA1MAPK1 | |
| SCHEMBL8686417 | 0.85 | GBA1 (0.53) | GJB2TNFIGF2RGBA1MAPK1 | |
| SCHEMBL15482117 | 0.83 | GJB2 (0.46) | GJB2TNFIGF2RGBA1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348414-A1 | NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES | WAYNE STATE UNIVERSITY (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348414-A1 | NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES | ERG28, DDOST, STT3A | GJB2 4753/4885TNF 2514/4885IGF2R 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.